In the current study, nine patients (37.49%) in the MetS group (Table 2) were taking angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor antagonists, a fact that may have, at some degree, contributed to reduce the effects of the renin-angiotensin system in the vascular wall. The gene discussed is ACE; the disease is metabolic syndrome.